BioInvent International AB (CHIX:BINVS) Cyclically Adjusted Book per Share: kr28.63 (As of Mar. 2026)


CHIX:BINVS BioInvent International AB CHIX:BINVS
39 GF Score
Price kr34.75
GF Value kr74.68
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Cyclically Adjusted Book per Share?

BioInvent International AB CHIX:BINVS 39 Cyclically Adjusted Book per Share is kr28.63 as of Mar. 2026. GuruFocus rates CHIX:BINVS with a GF Score™ of 39/100 and a GF Value™ of kr74.68. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BioInvent International AB's adjusted book value per share for the three months ended in Mar. 2026 was kr6.673. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr28.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BioInvent International AB's average Cyclically Adjusted Book Growth Rate was 1.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BioInvent International AB was 7.80% per year. The lowest was -17.10% per year. And the median was -2.90% per year.

As of today (2026-07-11), BioInvent International AB's current stock price is kr34.75. BioInvent International AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was kr28.63. BioInvent International AB's Cyclically Adjusted PB Ratio of today is 1.21.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioInvent International AB was 3.58. The lowest was 0.83. And the median was 1.87.


BioInvent International AB  (CHIX:BINVs) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BioInvent International AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=34.75/28.63
=1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioInvent International AB was 3.58. The lowest was 0.83. And the median was 1.87.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BioInvent International AB Cyclically Adjusted Book per Share Related Terms


BioInvent International AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Cyclically Adjusted Book per Share Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.11 17.38 32.81 16.30 21.62

BioInvent International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.47 18.39 22.41 21.62 28.63

CHIX:BINVS vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BioInvent International AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Cyclically Adjusted PB Ratio falls into.


CHIX:BINVS
39GF Score
BioInvent International AB CHIX:BINVS
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioInvent International AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.673/133.5600*133.5600
=6.673

Current CPI (Mar. 2026) = 133.5600.

BioInvent International AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 18.428 101.019 24.364
201609 15.958 101.138 21.074
201612 18.525 102.022 24.252
201703 16.728 102.022 21.899
201706 14.840 102.752 19.289
201709 13.135 103.279 16.986
201712 10.469 103.793 13.471
201803 12.979 103.962 16.674
201806 9.953 104.875 12.675
201809 8.404 105.679 10.621
201812 6.118 105.912 7.715
201903 5.971 105.886 7.532
201906 12.106 106.742 15.148
201909 10.302 107.214 12.834
201912 8.294 107.766 10.279
202003 6.680 106.563 8.372
202006 8.139 107.498 10.112
202009 17.115 107.635 21.237
202012 18.882 108.296 23.287
202103 26.769 108.360 32.995
202106 25.793 108.928 31.626
202109 24.722 110.338 29.925
202112 23.379 112.486 27.759
202203 22.221 114.825 25.847
202206 25.096 118.384 28.313
202209 25.924 122.296 28.312
202212 24.722 126.365 26.130
202303 23.765 127.042 24.984
202306 22.435 129.407 23.155
202309 21.371 130.224 21.919
202312 19.903 131.912 20.152
202403 18.732 132.205 18.924
202406 16.679 132.716 16.785
202409 15.244 132.304 15.389
202412 13.461 132.987 13.519
202503 11.697 132.825 11.762
202506 12.321 133.699 12.308
202509 10.380 133.480 10.386
202512 8.474 133.390 8.485
202603 6.673 133.560 6.673

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr28.63 mean?
BioInvent International AB (CHIX:BINVS) has a Cyclically Adjusted Book per Share of kr28.63 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioInvent International AB and its competitors.
Is BioInvent International AB's Cyclically Adjusted Book per Share too high?
BioInvent International AB's current Cyclically Adjusted Book per Share is kr28.63. Overall, BioInvent International AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
BioInvent International AB's Cyclically Adjusted Book per Share of kr28.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Cyclically Adjusted Book per Share is kr28.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (CHIX:BINVS) has a current Cyclically Adjusted Book per Share of kr28.63. The stock's GF Value™ is kr74.68, compared to a current price of kr34.75 — trading 53.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is kr28.63. BioInvent International AB's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BioInvent International AB (CHIX:BINVS), the current Cyclically Adjusted Book per Share is kr28.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioInvent International AB (CHIX:BINVS) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of kr34.75 is trading 53.5% below its estimated GF Value™ of kr74.68.

Key valuation signals for CHIX:BINVS:

  • Cyclically Adjusted Book per Share: kr28.63
  • GF Value™: kr74.68 vs. price of kr34.75 (53.5% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the CHIX:BINVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
39GF Score

Get the complete analysis for CHIX:BINVS

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.75
Price
kr74.68
GF Value